Long-term safety of TAK-861 in people with narcolepsy type 1
Checks long-term safety of TAK-861 in people with narcolepsy type 1.
Key facts
- Who runs it
- Takeda
- Where
- Atlanta, Birmingham, Charleston, Cincinnati, Cleveland, Colorado Springs, Columbia, Denver, Dublin, Gainesville, Huntersville, Newton, Norfolk, Novi, Orlando, Redwood City, San Antonio, and Santa Ana, United StatesSee the 19 sitesAlso in 14 other countries, 43 sites
- Trial code
- NCT05816382
- EU 2023-508462-15-00
- EudraCT 2022-002965-13
- JRCT2031230135
- U1111-1283-1888
- Registry title
- A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 500 people, planned
- Started
- 5 Apr 2023
- Expected to end
- 28 Feb 2028
- Type of study
- Interventional
- Treatments tested
- TAK-861
- Record updated
- 5 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with narcolepsy type 1 (NT1) who have finished an earlier controlled trial of TAK-861. It tests the long-term safety of TAK-861.
- Age
- 16 Years to 70 Years
- Sex
- All sexes
- Disease stage
- Narcolepsy type 1 (narcolepsy with cataplexy, sudden muscle weakness).
- Earlier treatment
- Must have completed a controlled trial with TAK-861. People who stopped the earlier trial because of side effects cannot join.
- Biomarker or test result
- ALT and AST liver tests must not be > 1.5 times the upper limit of normal (ULN).
Main reasons for not taking part
- A side effect from the earlier trial drug that is still severe
- Risk of suicide, or major depression now or in the past 6 months
- Epilepsy or a history of seizures
- History of stroke, brain bleeding, heart attack, heart failure or serious heart disease
- Cancer in the past 5 years
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Participant with a diagnosis of NT1 who has completed a controlled trial with TAK-861, and for whom the investigator has no clinical objection to their enrollment
Who cannot take part
- Participant has a current medical disorder, other than narcolepsy with or without cataplexy, associated with excessive daytime sleepiness (EDS)
- Participant has developed (within the last 6 months) gastrointestinal disease that is expected to influence the absorption of drugs
- Participant has epilepsy or history of seizure
- Participant has any other medical condition, such as anxiety, depression, heart disease, or significant hepatic, pulmonary, or renal disease, that requires them to take excluded medications
- Participant has a history of cerebral ischemia, transient ischemic attack (less than (<) 5 years ago), or cerebral hemorrhage
- Participant has a history of myocardial infarction, clinically significant coronary artery disease, clinically significant angina, clinically significant cardiac rhythm abnormality, or heart failure
- Participant has a history of cancer in the past 5 years
- The participant has alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values greater than (>) 1.5 times the upper limit of normal (ULN)
- Participant has a treatment-emergent adverse event (TEAE) that remains severe at the time of rollover related to the trial intervention from the parent trial or discontinued because of TEAEs in the parent trial
- Participant has a risk of suicide according to endorsement of item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS)
- Participant has current active major depressive episode (MDE) or has had an active MDE in the past 6 months
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 70 years old?
Where in United States
Also in 14 other countries, 43 sites
- NeuroTrials ResearchAtlanta, United StatesTaking people
- Sleep Disorders Center of AlabamaBirmingham, United StatesTaking people
- Medical University of South Carolina - PPDSCharleston, United StatesTaking people
- CTI Research CenterCincinnati, United StatesTaking people
- Intrepid ResearchCincinnati, United StatesTaking people
- The Cleveland Clinic FoundationCleveland, United StatesTaking people
- Delta Waves LLC - Hunt - PPDSColorado Springs, United StatesTaking people
- Bogan Sleep Consultants, LLCColumbia, United StatesTaking people
- Research Carolina EliteDenver, United StatesTaking people
- Ohio Sleep Medicine InstituteDublin, United StatesTaking people
- Georgia Neuro CenterGainesville, United StatesTaking people
- ARSM Research, LLCHuntersville, United StatesTaking people
- Neurocare, Inc.Newton, United StatesTaking people
- Children's Specialty GroupNorfolk, United StatesTaking people
- Henry Ford Medical Center-ColumbusNovi, United StatesTaking people
- Florida Pediatric Research InstituteOrlando, United StatesTaking people
- Stanford Center for Sleep Sciences and MedicineRedwood City, United StatesTaking people
- Sleep Therapy and Research CenterSan Antonio, United StatesTaking people
- SDS Clinical Trials, Inc.Santa Ana, United StatesTaking people
About the trial
What the trial wants to find out
The main aim is to evaluate the safety and tolerability of TAK-861 in participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
The group in the trial
- TAK-861Treatment being tested
In this trial, all participants are on TAK-861 treatment and they can switch to one of the available doses as needed.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions
- Plain-language title
- Long-term safety of TAK-861 in people with narcolepsy type 1Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05816382, who can take part
- Record updated
- 5 March 2026